As of March 1, 2022, CiMaas is a licensed manufacturer for cell-based products. The company received the manufacturing authorization from the Dutch Ministry of Health, Welfare and Sport – Farmatec/CIBG.
The license allows CiMaas to manufacture and release its’ dendritic cell vaccine for use in patients suffering from cancer.
The authorization is based on the approval by the Dutch Inspectorate of Health and Youth of the CiMaas standard operating procedures and its quality management system.
“This is a major step forward in gearing up towards our first clinical trial in non-small cell lung cancer” comments CEO Gerard Bos.
“We are very happy with this license, indicating the quality level CiMaas has reached over the past years and is now allowed to manufacture cell based products” adds Quality Manager Reinout Hesselink.Farmatec, GMP, Manufacturing license